VANCOUVER, BC — January 29, 2026 — Leads & Copy — LIR Life Sciences Corp. has announced positive interim results from its comparative mouse study. The study evaluates cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies.
The interim analysis revealed that animals treated with a novel semaglutide/CPP topical formulation experienced reduced blood glucose after an oral glucose challenge, compared to untreated controls. This indicates pharmacologically meaningful activity.
The study compares a topical, skin-applied CPP formulation of semaglutide, a GLP-1 analogue representative of GLP/GIP-based therapies, against injectable semaglutide and untreated controls in a glucose tolerance model. According to the company, the interim data represent one of the first demonstrations in a controlled in vivo setting that a CPP-enabled topical formulation of a GLP/GIP-based therapy can approach the glucose control profile of an injectable comparator.
The company reported observing a flattened glucose curve from a skin-applied formulation, calling it a key technical milestone for its platform. This supports the scientific thesis that CPP-based systems may be able to move large peptide drugs across the skin barrier at levels that are functionally meaningful in a standard metabolic model.
According to the release, animals that received the CPP-formulated topical semaglutide showed a reduction in blood glucose compared with untreated controls following a standardized oral glucose challenge. The company noted that while control animals exhibited a pronounced spike in blood sugar after glucose administration, both the injected semaglutide group and the CPP-enabled topical group demonstrated effective blunting of this spike and a faster return toward baseline. Blood glucose levels in the CPP topical group remained stable over the observation period.
LIR Life Sciences stated that these findings indicate that the CPP-enabled topical formulation is delivering active drug across the skin barrier at pharmacologically meaningful levels and is achieving sustained glucose control in this model.
According to the company, these interim results provide preliminary in vivo support for LIR’s CPP-enabled transdermal platform for GLP/GIP-based therapies. The demonstration with topical CPP semaglutide is an important step toward refining formulations, confirming dose ranges and guiding the path to future studies.
These findings also support the continued funding of an existing comparative study utilizing a different GLP/GIP-based therapy, for which results are anticipated shortly.
LIR Life Sciences CEO Edward Mills said the company is encouraged by what the study is showing, even at this interim stage. Mills added that the CPP-enabled topical formulation is producing a meaningful glucose-lowering effect in a standard model. He stated that this supports the thesis of pursuing a needle-free approach and gives the company a clear basis for the next phase of work, including refining the formulation, narrowing the dose range, and completing the additional comparative studies already underway.
LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. The company believes that these therapies could potentially offer an alternative to injectable drugs with the goal of improving access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.
Source: LIR Life Sciences Corp.
